The first female CEO has been appointed in the Korean pharmaceutical industry.
Bukwang Pharm recently held a board of directors meeting and appointed Vice President Yu Hee-won as co-President of Bukwang Pharm with President Kim Sang-hoon.
The newly-appointed President Yu graduated from the college of pharmacy in Ewha Womans University and acquired a doctoral degree in the graduate school of the university. Previously, Yu worked as a research student at the National Institutes of Health from 1995 to 1997 and has worked at Bukwang Pharm since 1999.
Yu said, “We will put efforts together to develop new medicines and contribute to sales growth as well by concentrating in research and development.”
Bukwang Pharm plans to successfully complete an anti-cancer drug Apatinib Mesylate, with which it is carrying out the second phase of the former half simultaneously in Korea and the U.S., and a medicine for diabetes (MLR-1023).
Bukwang Pharm will also carry out a clinical demonstration of JM-010, LID medicine from Contera Pharma within the year, which Bukwang took over last year.
An official from the pharmaceutical industry said, “Women CEOs are standing out, showing excellent performances in the multinational pharmaceutical industry,” adding, “Woman power will be expected in the Korean pharmaceutical industry with the appointment of President Yu.”